Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pseudovax and Tislelizumab in Pseudomyxoma Peritonei
NCT07341360Phase 1Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2029
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Pseudovax in pseudomyxoma peritonei (PMP), sponsored by Oslo University Hospital. Primary endpoints: Safety and tolerability and Immune responses at 2 years. Started Oct 2025; status: recruiting.
02
Drugs
Pseudovax
03
Conditions
pseudomyxoma peritonei (PMP)
Beyond the preview
Go deeper on NCT07341360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07341360.